|88005C||1 Kit (96 assays)||$ 629|
|Product Includes||Volume||Solution Color|
|Spike Multi-Domain Protein Coated Microwells||96 tests|
|Anti-Human IgG, HRP-linked Antibody (ELISA Formulated)||1 ea||Red (Lyophilized)|
|Sample Diluent A 71637||25 ml|
|HRP Diluent||11 ml||Red|
|ELISA Wash Buffer (20X) 9801||25 ml|
|TMB Substrate 7004||11 ml|
|STOP Solution 7002||11 ml|
|Sealing Tape||2 ea|
|ELISA Kit #88005 Positive Control||1 ea|
|ELISA Kit #88005 Negative Control||1 ea|
This ELISA Kit Is Intended For Research Use Only. Not For Use in Diagnostic or Clinical Procedures.
NOTE: Prepare solutions with deionized/purified water or equivalent. Prepare only as much reagent as needed on the day of the experiment.
Positive Control: Reconstitute the vial of lyophilized Positive Control with 1.0 mL Sample Diluent A. Mix thoroughly and gently, hold at room temperature for 1 minute and then follow the steps outlined below in the “Test Procedure” section. Positive Controls are recommended to be used immediately after reconstituting, however remaining material may be stored at -80°C (there may be some loss of the Positive Control signal if freeze/thawed). Positive Controls are supplied as a control reagent, not as an absolute quantitation measure.
IMPORTANT: This control is intended to give a positive signal for the RBD and S1 coated microwell strips, and is NOT a positive control for the S1-NTD or S2 microwells.
NOTE: Equilibrate all materials and prepared reagents to room temperature prior to running the assay.
Human-sourced samples should be handled in accordance with accepted safety practices. Samples should be diluted at least 1:400 with Sample Diluent A and can be further serially diluted if relative quantification is needed by the user. Positive and Negative Controls do NOT need to be diluted after reconstitution. Refer to the datasheet which shows typical results observed for the Positive Control, Negative Control, serum from uninfected individuals, and serum from SARS-CoV-2 patients. When using the cutoff criteria described below to determine if a sample is positive for anti-CoV-2 Spike Protein antibodies, samples diluted 1:400 must be compared to the undiluted Negative Control.
NOTE: Sample storage/handling, including heat-inactivation of samples, can potentially affect observed signals. Therefore, it is strongly recommended that in addition to the Positive and Negative Controls included with the kit, the user includes their own negative and positive patient samples as controls when running the assay in order to establish an appropriate cutoff value.
Add 100 µL of STOP Solution to each well. Shake gently for a few seconds.
NOTE: Initial color of positive reaction is blue, which changes to yellow upon addition of STOP Solution.
|Positive Criteria||Negative Criteria||Inconclusive Criteria|
|S1-NTD||> 1.7 x Negative Control||< 1.35 x Negative Control||> 1.35 x Negative Control and < 1.7 x Negative Control|
|RBD||> 3.4 x Negative Control||< 2.7 x Negative Control||> 2.7 x Negative Control and < 3.4 x Negative Control|
|S1||> 4 x Negative Control||< 3 x Negative Control||> 3 x Negative Control and < 4 x Negative Control|
|S2||> 4.1 x Negative Control||< 3.1 x Negative Control||> 3.1 x Negative Control and < 4.1 x Negative Control|
Limitations: Experimental cutoffs were determined by assaying a set of SARS-CoV-2 positive samples (from donors with positive SARS-CoV-2 diagnosis) and uninfected donor serum collected prior to the SARS-CoV-2 pandemic.
NOTE: Positive reference samples were from patient donors with a positive SARS-CoV-2 diagnosis. However, a positive SARS-CoV-2 diagnosis will not always correlate with a positive response against each spike domain protein in this IgG Serological ELISA as differences in disease severity, timing of sample collection relative to disease onset, and patient profiles may affect presence and abundance of antibodies against each spike domain in the reference sample.
Researchers can establish or modify this cutoff using additional samples. Positive or negative results from this assay should not be the sole basis for determining the infection status of a sample. A negative result can occur in SARS-CoV-2 patient samples due to:
NOTE: Absorbance 450 nm values should not be directly compared across different spike domain proteins, as they are not absolute values.
posted September 2020
Protocol Id: 2306
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.